Bamlanivimab reduces risk of COVID-19 in nursing homes, study findsPreventive use of bamlanivimab lowered the risk of symptomatic COVID-19 in staff and residents of skilled nursing and assisted living facilities in the United States, according to a study yesterday in JAMA.In April, after the study was conducted, the US Food and Drug Administration rescinded emergency use authorization for the monoclonal antibody (mAb) when used alone because of resistance of SARS-CoV-2 variants to the drug.
A treatment of bamlanivimab and etesevimab is still allowed.The researchers enrolled 666 staff and 300 residents with no history of SARS-CoV-2 from Aug 2 to Nov 2, 2020, with half receiving one dose of 4,200 milligrams of bamlanivimab and the other half